Pathstone Family Office’s Lexicon Pharmaceuticals LXRX Stock Holding History

Pathstone Family Office’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-90	Closed	–	–	864
2020 Q1	$0	Buy	+90	New	+$268	﹤0.01%	800

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Pathstone Family Office's LXRX Position: Q2 2020 in Review

Pathstone Family Office sold out of Lexicon Pharmaceuticals (LXRX) in Q2 2020, closing a stake of 90 shares.

Pathstone Family Office first reported a position in LXRX in Q1 2020 and held it in 1 quarter. The position peaked at $0 in Q1 2020. 108 funds tracked by Wall St. Rank hold LXRX as of Q2 2020.

Pathstone Family Office reported no remaining Lexicon Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
Pathstone Family Office sold 90 Lexicon Pharmaceuticals shares in Q2 2020.
Pathstone Family Office first reported a position in Lexicon Pharmaceuticals in Q1 2020 and held it in 1 quarter.
Pathstone Family Office's Lexicon Pharmaceuticals position peaked at $0 in Q1 2020.
108 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2020.

Based on Pathstone Family Office's 13F filing for Q2 2020, filed 14 Aug 2020.